Expert opinion on drug delivery最新文献_第4页

Mechanism-guided metal complex therapeutics for biofilm-driven wound infections and transdermal delivery. 机制导向的金属复合物治疗生物膜驱动的伤口感染和透皮给药。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-09-01 Epub Date: 2026-07-04 DOI: 10.1080/17425247.2026.2697993

Soumojit Maji, Sumana M N, Sasvin Paramasivam, Shobana Rajaramon, Swathi Sujith, Adline Princy Solomon, Mukesh Pasupuleti

{"title":"Mechanism-guided metal complex therapeutics for biofilm-driven wound infections and transdermal delivery.","authors":"Soumojit Maji, Sumana M N, Sasvin Paramasivam, Shobana Rajaramon, Swathi Sujith, Adline Princy Solomon, Mukesh Pasupuleti","doi":"10.1080/17425247.2026.2697993","DOIUrl":"10.1080/17425247.2026.2697993","url":null,"abstract":"Introduction: Chronic wound infections remain a major healthcare challenge due to persistent polymicrobial biofilms and the increasing prevalence of antimicrobial resistance. Conventional antimicrobial therapies often fail to eradicate biofilms, highlighting the need for innovative therapeutic strategies. Metal complexes have emerged as promising candidates owing to their multitarget antimicrobial and antibiofilm activities and potential for localize wound treatment.Areas covered: This review examines the role of metal complexes in combating biofilm-associated wound infections. Their mechanisms of action, including membrane disruption, redox imbalance, quorum-sensing inhibition, metabolic interference, and biofilm matrix destabilization, are discussed. The review further explores the integration of metal complexes into advanced transdermal and wound patch platforms, including polymeric matrices, nanocomposite systems and stimuli-responsive delivery systems designed to enhance localized drug release, improve wound retention, and minimize systemic toxicity. Current preclinical and translational developments are also highlighted.Expert opinion: Metal-complex-based transdermal therapeutics represent a promising next-generation approach for managing chronic biofilm-mediated wound infections and overcoming antimicrobial resistance. However, successful clinical translation requires addressing challenges related to toxicity, formulation stability, manufacturing scalability, regulatory approval, and long-term safety. Future interdisciplinary efforts integrating microbiology, materials science, and clinical research will be essential to advance these technologies from laboratory to clinical practice.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1601-1626"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148364580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Next-generation strategies for PROTAC formulation: mechanistic insights and advanced formulation technologies. 新一代PROTAC配方策略：机制洞察和先进配方技术。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-09-01 Epub Date: 2026-07-06 DOI: 10.1080/17425247.2026.2697992

Azad Kumar Maurya, Luis Padrela, Ashish K Agrawal, Ashish Kumar, Dinesh Kumar

{"title":"Next-generation strategies for PROTAC formulation: mechanistic insights and advanced formulation technologies.","authors":"Azad Kumar Maurya, Luis Padrela, Ashish K Agrawal, Ashish Kumar, Dinesh Kumar","doi":"10.1080/17425247.2026.2697992","DOIUrl":"10.1080/17425247.2026.2697992","url":null,"abstract":"Introduction: Proteolysis-targeting chimeras (PROTAC) are an innovative treatment approach that selectively breaks down disease-relevant proteins by utilizing the ubiquitin-proteasome system. Other than PROTAC, Molecular glue, Lysosome-Targeting Chimaera (LYTAC), GlueTAC, Autophagy-Targeting Chimaera (AUTAC), Autophagosome Tethering Compound (ATTEC), and Antibody-based PROTAC (AbTAC) are emerging targeted protein degradation (TPD) techniques, of which PROTAC offers several benefits.Areas covered: This review discusses the development of proteolysis-targeting chimeras (PROTACs) for targeted protein degradation, highlighting their mechanism of action via the ubiquitin-proteasome system. It examines key physicochemical and pharmacokinetic challenges that limit clinical translation. Advanced formulation strategies, including nanoformulations and amorphous solid dispersions, prodrug improve solubility, bioavailability, and therapeutic efficacy. Additionally, characterization techniques are summarized, and the review outlines recent progress and critical considerations for the successful clinical translation of PROTAC-based therapeutics. Relevant articles from PubMed, Scopus, and Web of Science, spanning publications up to 2026, were gathered.Expert opinion: PROTACs represent a transformative therapeutic modality, enabling selective protein degradation beyond conventional inhibition. Future research should focus on improving bioavailability, targeted delivery, and stability, while advancing prodrug strategies, E3 ubiquitin ligase selectivity, oral formulations, and predictive models for clinical translation. Additionally, it should emphasize scalable manufacturing, regulatory frameworks, and integration with emerging targeted protein degradation technologies.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1639-1662"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148364160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond bioequivalence: a critical overview of the innovator AmBisome as the reference standard for liposomal amphotericin B generics. 超越生物等效性：创新AmBisome作为脂质体两性霉素B仿制药参考标准的关键概述。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-09-01 Epub Date: 2026-06-26 DOI: 10.1080/17425247.2026.2694580

Francelise Bridi Cavassin, Marcello Mihailenko Chaves Magri

{"title":"Beyond bioequivalence: a critical overview of the innovator AmBisome as the reference standard for liposomal amphotericin B generics.","authors":"Francelise Bridi Cavassin, Marcello Mihailenko Chaves Magri","doi":"10.1080/17425247.2026.2694580","DOIUrl":"10.1080/17425247.2026.2694580","url":null,"abstract":"Introduction: The advent of liposomal amphotericin B (L-AmB, commercialized as AmBisome) technology represented a paradigm shift in antifungal drug delivery, substantially reducing the severe, well-known nephrotoxicity historically associated with the conventional deoxycholate formulation (D-AmB). Despite this advance, the expiration of the innovator's patent has spurred the global development of generic liposomal preparations, raising critical biopharmaceutical and clinical safety concerns.Areas covered: This article reviews the literature and regulatory landscape of L-AmB and its nanosimilars. A comprehensive search was performed using PubMed, Embase, and Web of Science (1990-2026), focusing on NBCDs, bioequivalence, and clinical safety. The scope includes an evaluation of marketed generic formulations, their regulatory registrations, and published comparative studies. We also discuss the clinical consequences of administering unstable generics during high-dose protocols.Expert opinion: While recognizing the urgent need for affordable generic alternatives to democratize access in low- and middle-income countries (LMICs), we emphasize the necessity of stringent, internationally harmonized regulatory standards that go beyond conventional bioequivalence. Safeguarding biopharmaceutical fidelity is an indispensable clinical imperative to protect vulnerable patients from the severe hidden costs of therapeutic failure and drug-induced toxicity.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1627-1638"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148341527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug penetration in solid tumors: influence of drug size and capillary architecture. 实体肿瘤中药物侵彻：药物大小和毛细血管结构的影响。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-09-01 Epub Date: 2026-07-02 DOI: 10.1080/17425247.2026.2696892

Hooman Salavati, Massimo Lai, Cesar Pichardo-Almarza, Holly Kimko, Wim Ceelen

{"title":"Drug penetration in solid tumors: influence of drug size and capillary architecture.","authors":"Hooman Salavati, Massimo Lai, Cesar Pichardo-Almarza, Holly Kimko, Wim Ceelen","doi":"10.1080/17425247.2026.2696892","DOIUrl":"10.1080/17425247.2026.2696892","url":null,"abstract":"Introduction: Macromolecular and nanoparticulate drug carriers are increasingly important in oncology due to improved targeting and reduced systemic toxicity; however, their delivery to solid tumors is often limited by size-dependent transport barriers.Methods: We present a computational modeling framework that couples microvascular blood flow, transvascular exchange, interstitial fluid flow, and macromolecule transport to investigate the interplay between drug properties, particularly particle size, and tumor capillary structural characteristics. A stochastic capillary network generation algorithm was developed to produce realistic microvascular networks with heterogeneous vessel radius, branching patterns, and permeability properties.Results: Simulations show an inverse relationship between particle size and penetration and quantify how pore radius and pore area fraction modulate extravasation and tissue dispersion.Conclusions: Overall, the framework may serve as a prototype in silico tool for drug formulation design, supporting the selection of molecular formats and sizes that distribute more efficiently within tumors under tumor-specific biophysical constraints.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1733-1743"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148355250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rethinking the evaluation of intra-articular drug delivery systems for osteoarthritis. 对骨关节炎关节内给药系统评价的再思考。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-09-01 Epub Date: 2026-07-03 DOI: 10.1080/17425247.2026.2693498

Qing Yao, Yuzhi Zhang, Ruijie Chen

引用次数: 0

Dry powder inhaler selection in COPD: integrating device design, formulation performance, and patient inspiratory capability. COPD中干粉吸入器的选择：整合装置设计、配方性能和患者吸入能力。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-09-01 Epub Date: 2026-07-06 DOI: 10.1080/17425247.2026.2699327

Michał Pirożyński

{"title":"Dry powder inhaler selection in COPD: integrating device design, formulation performance, and patient inspiratory capability.","authors":"Michał Pirożyński","doi":"10.1080/17425247.2026.2699327","DOIUrl":"10.1080/17425247.2026.2699327","url":null,"abstract":"Introduction: Appropriate dry powder inhaler (DPI) selection is essential for effective COPD management because pulmonary drug delivery depends on interactions between formulation properties, device design, and patient capability. This review proposes a Formulation-Device-Patient (FDP) matching framework to support individualized DPI selection.Areas covered: A structured search of PubMed and Google Scholar identified publications on COPD, DPI selection, inspiratory flow, device resistance, aerosol performance, inhaler technique, usability, and formulation-device interactions. Evidence shows that DPIs differ substantially in internal resistance, inspiratory-flow requirements, dose-preparation mechanisms, aerosolization characteristics, handling complexity, and feedback systems, and therefore should not be considered interchangeable. Appropriate device selection requires assessment of inspiratory capability alongside manual dexterity, cognitive function, comorbidities, prior inhaler experience, patient preference, and inhaler technique. The review also highlights the limitations of direct cross-device comparisons and cautions against interpreting in vitro aerosol-performance metrics as indicators of clinical superiority.Expert opinion: DPI selection should move beyond device-centered prescribing toward individualized formulation-device-patient matching. The proposed FDP framework provides a practical model for individualized DPI selection by integrating formulation characteristics, device engineering, and patient capability rather than relying on inspiratory flow or device characteristics alone.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1685-1699"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148378742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ligand-functionalized liposomal vesicles in breast cancer: advances in targeted nanotherapeutics. 配体功能化脂质体囊泡在乳腺癌中的应用：靶向纳米治疗的进展。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-09-01 Epub Date: 2026-06-12 DOI: 10.1080/17425247.2026.2685776

Rohit Sharma, Kamal Dua, Vetriselvan Subramaniyan, Thakur Gurjeet Singh

{"title":"Ligand-functionalized liposomal vesicles in breast cancer: advances in targeted nanotherapeutics.","authors":"Rohit Sharma, Kamal Dua, Vetriselvan Subramaniyan, Thakur Gurjeet Singh","doi":"10.1080/17425247.2026.2685776","DOIUrl":"10.1080/17425247.2026.2685776","url":null,"abstract":"Introduction: Breast cancer (BC) remains one of the most prevalent malignancies worldwide, characterized by molecular heterogeneity, therapeutic resistance, and high recurrence rates that limit the success of conventional treatments. Although chemotherapy and targeted therapies have improved patient outcomes, their effectiveness is often compromised by off-target toxicity, poor tumor selectivity, and multidrug resistance. Liposomal nanocarriers improves drug stability and circulation while enhancing passive tumor accumulation via the EPR effect. However, conventional liposomes exhibit limited cellular internalization and inadequate tumor penetration.Area covered: This review discusses ligand-functionalized liposomes for active targeting in BC. Surface modification with antibodies, peptides, aptamers, carbohydrates, and small molecules enables selective binding to overexpressed receptors, improving cellular uptake and intracellular drug delivery. The literature was screened using PubMed, ScienceDirect, Google Scholar, and Scopus. Recent advances in multifunctional systems, including dual-targeting strategies, stimuli-responsive release mechanisms, and combination therapies, are also examined.Conclusion: Ligand-modified liposomes show strong potential to enhance therapeutic precision, pharmacokinetics, and safety. These have the potential of targeted delivery, decreased toxicity, and improved therapeutic effects. However, challenges such as tumor heterogeneity, large-scale manufacturing, and regulatory constraints must be addressed for successful clinical translation.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1579-1599"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148201835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bioinspired synthetic strategies for enhanced cell membrane interactions for targeted delivery of biomacromolecules. 增强细胞膜相互作用的生物大分子靶向递送的生物启发合成策略。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-09-01 Epub Date: 2026-07-15 DOI: 10.1080/17425247.2026.2702442

Nicole Henry, Apanpreet Kaur, Rongjun Chen

{"title":"Bioinspired synthetic strategies for enhanced cell membrane interactions for targeted delivery of biomacromolecules.","authors":"Nicole Henry, Apanpreet Kaur, Rongjun Chen","doi":"10.1080/17425247.2026.2702442","DOIUrl":"10.1080/17425247.2026.2702442","url":null,"abstract":"Introduction: Biomacromolecular therapeutics, including proteins and nucleic acids, offer high specificity but face major delivery challenges of stability, cellular uptake, and intracellular trafficking. Synthetic bioinspired strategies, ranging from systems that borrow broad principles from nature to biomimetic carriers that closely imitate biological mechanisms, are increasingly being explored to overcome these barriers.Areas covered: This review examines lipid- and polymer-based systems for protein and nucleic-acid delivery, drawn from two paradigms: virus-mimicking systems and peptide/protein pathway-based mimicry. Virus-mimicking platforms are divided into two groups: structural mimicry (capsid-like nanoparticles, fusogenic liposomes, dendrimers) and functional mimicry (pH-responsive endosomolytic and environmentally triggered systems). Pathway-based approaches span receptor-mediated blood-brain barrier transport, fibrinogen bridging for thrombus targeting, and charge-mediated membrane penetration. Relevant literature was identified through PubMed, Nature, Scopus and Web of Science, focusing on the last 15 years of innovation. Unlike reviews centered on membrane-coated biomimetic carriers or on a single modality or barrier, it uses the cell-membrane interaction as a unifying organizing principle across delivery of both cargo types.Expert opinion: Computational design, machine-learning-guided optimization and hybrid lipid-polymer architectures are expected to accelerate translation, while stimuli-responsive, multifunctional nanoparticles integrating targeting, controlled release and diagnostics will likely define the next generation of precision biomacromolecule delivery systems.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1663-1684"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148431740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How can we best utilize magnetic resonance for microbubble-mediated drug delivery to the brain. 我们怎样才能最好地利用磁共振技术将微泡介导的药物输送到大脑？

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-09-01 Epub Date: 2026-08-01 DOI: 10.1080/17425247.2026.2711975

Yuexi Huang, Kullervo Hynynen

{"title":"How can we best utilize magnetic resonance for microbubble-mediated drug delivery to the brain.","authors":"Yuexi Huang, Kullervo Hynynen","doi":"10.1080/17425247.2026.2711975","DOIUrl":"10.1080/17425247.2026.2711975","url":null,"abstract":"Introduction: Drug delivery to the brain is severely limited by the blood-brain barrier (BBB). Focused ultrasound (FUS) combined with intravenously administered microbubbles (MB) offers a promising noninvasive approach for transient and reversible BBB permeability enhancement.Areas covered: Magnetic resonance-guided FUS (MRgFUS) has been well established for thermal ablation, providing precise anatomical targeting and real-time thermometric feedback. Although BBB permeability enhancement does not rely on thermal effects, MRI guidance remains essential. This review highlights the role of MRI in BBB permeability enhancement procedures and summarizes MR sequences used at different stages to optimize targeting accuracy, safety, and therapeutic efficacy.Expert opinion: Because substantial temperature elevation is not expected during BBB permeability enhancement, MR thermometry is not routinely informative in this application. Nevertheless, MRI is central to anatomical and functional targeting for treatment planning and monitoring. Contrast-enhanced T1-weighted imaging enables assessment and localization of BBB permeability enhancement, while T2*-weighted imaging helps identify exposures approaching unsafe levels. Future clinical trials incorporating intraoperative MR guidance are needed to refine and standardize cavitation-based feedback control before developing and adopting systems that do not depend on intraoperative MRI.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1701-1712"},"PeriodicalIF":5.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148633325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarker-driven and AI-assisted nanomedicine for breast cancer: advancing precision drug delivery from bench to bedside. 生物标志物驱动和人工智能辅助的乳腺癌纳米医学：推进从实验室到床边的精准药物输送。

IF 5.4

Expert opinion on drug delivery Pub Date : 2026-08-01 Epub Date: 2026-06-05 DOI: 10.1080/17425247.2026.2680061

Jaleh Barar, Rais Ansari, Yadollah Omidi

{"title":"Biomarker-driven and AI-assisted nanomedicine for breast cancer: advancing precision drug delivery from bench to bedside.","authors":"Jaleh Barar, Rais Ansari, Yadollah Omidi","doi":"10.1080/17425247.2026.2680061","DOIUrl":"10.1080/17425247.2026.2680061","url":null,"abstract":"Introduction: Breast cancer remains the most prevalent malignancy among women worldwide, with its pronounced molecular heterogeneity demanding therapeutic strategies that transcend conventional systemic chemotherapy toward tumor-selective, molecularly precise interventions. The convergence of biomarker science, engineered nanomedicine, and artificial intelligence (AI) offers a transformative framework for realizing this goal.Areas covered: This review examines how molecular biomarkers (e.g. mucin glycoproteins, human epidermal growth factor receptor 2 (HER2), circulating tumor cells, and circulating tumor DNA) serve dual roles as diagnostic identifiers and active targeting ligands directing engineered nanocarriers. We critically evaluate biomarker-guided nanoplatforms (liposomal, polymeric, metallic, and protein-based architectures), stimuli-responsive drug release strategies, and AI-driven microfluidic manufacturing for scalable, good manufacturing practice-compliant nanoparticle production. Literature was retrieved from PubMed/MEDLINE, Scopus, and Web of Science (2000-2026), supplemented by ClinicalTrials.gov data.Expert opinion: Near-term clinical impact is most realistically achieved through AI-assisted biomarker interpretation and multi-analyte liquid biopsy integration rather than novel nanoformulations, whose translational attrition remains high. Bridging the bench-to-bedside gap requires prospective biomarker-stratified clinical trials, co-developed companion diagnostics, and federated AI architectures as advances that will progressively replace static histological subtype classification with a continuously updated, molecularly individualized treatment paradigm for breast cancer.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1447-1477"},"PeriodicalIF":5.4,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148159389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0